MicroRNA-186-5p Represses Neuroblastoma Cell Growth Via Downregulation of

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2019 May 21

PMID 31105832

Citations 8

Authors

Kai Zhu

Yilin Su

Bing Xu

Zhongrong Wang

Hua Sun

Liang Wang

Chuancheng Sun

Xiaorui He

Affiliations

Soon will be listed here.

Abstract

Micro RNA (miRNAs) is a kind of non coding small RNAs with negative regulation function, which plays an important role in regulating the occurrence and development of tumors. In this study, we analyzed the expression level and role of miRNA-186-5p and Eg5 in neuroblastoma and neuroblastoma cell lines SHSY-5Y, Kelly, NBL-S and SK-N-AS. Results of Real-time PCR and immunohistochemistry showed that the expression level of Eg5 in tumor tissues was higher than that in tumor adjacent tissues, while miRNA-186-5p expression level in tumor tissues was lower than that in tumor adjacent tissues. miRNA-186-5p mimics or Eg5 siRNA was transfected into SHSY-5Y and Kelly cells, CCK-8 and soft agar clone formation tests' results showed that the cell proliferation was inhibited. Flow cytometry analysis of cell apoptosis and cell cycle showed that overexpression of Mi-186-5p or down-regulation of Eg5 could promote cell apoptosis and lead to arrest cell cycle at G1 phase. Bioinformatics predicts that miRNA-186-5p can bind to the 3'UTR of Eg5. Luciferase reporter gene analysis and Western blot assay also confirmed that microRNA335-5p could target ICAM-1 to inhibit its expression. The tumor growth in nude mice inoculated SHSY-5Y cells with overexpression of miRNA-186-5p was inhibited. In a word, our study found that miR-186-5p could inhibit tumor proliferation by targeting Eg5 in neuroblastoma. This finding will help to better understand the pathogenesis of neuroblastoma and provide new insights into the treatment of tumors.

Citing Articles

Mitotic Functions and Characters of KIF11 in Cancers.

Gao W, Lu J, Yang Z, Li E, Cao Y, Xie L Biomolecules. 2024; 14(4).

PMID: 38672404 PMC: 11047945. DOI: 10.3390/biom14040386.

Specific downregulation of microRNA-186 induces neural stem cell self-renewal by upregulating Bmi-1/FoxG1 expression.

Chen T, Liu J, Liu Y, Chen Y, Wang X Hum Cell. 2023; 36(6):2016-2026.

PMID: 37700157 DOI: 10.1007/s13577-023-00981-9.

miRNA-186-5p inhibits migration, invasion and proliferation of breast cancer cells by targeting SBEM.

Hao H, Wang B, Yang L, Sang Y, Xu W, Liu W Aging (Albany NY). 2023; 15(14):6993-7007.

PMID: 37477531 PMC: 10415540. DOI: 10.18632/aging.204887.

Role of non-coding RNAs in neuroblastoma.

Anoushirvani A, Jafarian Yazdi A, Amirabadi S, Ahmadi Asouri S, Shafabakhsh R, Sheida A Cancer Gene Ther. 2023; 30(9):1190-1208.

PMID: 37217790 DOI: 10.1038/s41417-023-00623-0.

CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p.

Zhao L, Fan J, Zhang C, Zhang Z, Dong J Open Med (Wars). 2023; 18(1):20230672.

PMID: 36941992 PMC: 10024347. DOI: 10.1515/med-2023-0672.

References

Hansen G, Justice M . Activation of Hex and mEg5 by retroviral insertion may contribute to mouse B-cell leukemia. Oncogene. 1999; 18(47):6531-9. DOI: 10.1038/sj.onc.1203023. View

Kwok B, Yang J, Kapoor T . The rate of bipolar spindle assembly depends on the microtubule-gliding velocity of the mitotic kinesin Eg5. Curr Biol. 2004; 14(19):1783-8. DOI: 10.1016/j.cub.2004.09.052. View

Kapitein L, Peterman E, Kwok B, Kim J, Kapoor T, Schmidt C . The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005; 435(7038):114-8. DOI: 10.1038/nature03503. View

Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K . Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer. 2006; 54(2):217-25. DOI: 10.1016/j.lungcan.2006.06.018. View

Carter B, Mak D, Shi Y, Schober W, Wang R, Konopleva M . Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle. 2006; 5(19):2223-9. DOI: 10.4161/cc.5.19.3255. View

Planas-Silva M, Filatova I . Estrogen-dependent regulation of Eg5 in breast cancer cells. Anticancer Drugs. 2007; 18(7):773-9. DOI: 10.1097/CAD.0b013e3280a02f2b. View

Castillo A, Morse 3rd H, Godfrey V, Naeem R, Justice M . Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res. 2007; 67(21):10138-47. DOI: 10.1158/0008-5472.CAN-07-0326. View

Hayashi N, Koller E, Fazli L, Gleave M . Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate. 2008; 68(12):1283-95. DOI: 10.1002/pros.20783. View

Nakai R, Iida S, Takahashi T, Tsujita T, Okamoto S, Takada C . K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res. 2009; 69(9):3901-9. DOI: 10.1158/0008-5472.CAN-08-4373. View

10.

Shimizu M, Ishii H, Ogo N, Unno Y, Matsuno K, Sawada J . S-trityl-L-cysteine derivative induces caspase-independent cell death in K562 human chronic myeloid leukemia cell line. Cancer Lett. 2010; 298(1):99-106. DOI: 10.1016/j.canlet.2010.06.007. View

11.

Ding S, Xing N, Lu J, Zhang H, Nishizawa K, Liu S . Overexpression of Eg5 predicts unfavorable prognosis in non-muscle invasive bladder urothelial carcinoma. Int J Urol. 2011; 18(6):432-8. DOI: 10.1111/j.1442-2042.2011.02751.x. View

12.

Jeison M, Yaniv I, Ash S . Genetic stratification of neuroblastoma for treatment tailoring. Future Oncol. 2011; 7(9):1087-99. DOI: 10.2217/fon.11.87. View

13.

Owens C, Irwin M . Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit Rev Clin Lab Sci. 2012; 49(3):85-115. DOI: 10.3109/10408363.2012.683483. View

14.

Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q . The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Med Oncol. 2013; 30(1):476. DOI: 10.1007/s12032-013-0476-0. View

15.

Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N . PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis. 2013; 34(9):2145-55. DOI: 10.1093/carcin/bgt158. View

16.

Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, Neukam F . miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014; 31(3):1429-36. DOI: 10.3892/or.2014.2983. View

17.

Wakui H, Yamamoto N, Kitazono S, Mizugaki H, Nakamichi S, Fujiwara Y . A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 74(1):15-23. DOI: 10.1007/s00280-014-2467-z. View

18.

Zhang Z, Bai Z, Wang X, Bai L, Miao F, Pei H . miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS One. 2015; 10(3):e0118814. PMC: 4351009. DOI: 10.1371/journal.pone.0118814. View

19.

Honegger A, Schilling D, Bastian S, Sponagel J, Kuryshev V, Sultmann H . Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog. 2015; 11(3):e1004712. PMC: 4356518. DOI: 10.1371/journal.ppat.1004712. View

20.

Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y . miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2015; 35(3):323-32. DOI: 10.1038/onc.2015.84. View